Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: In two recently published clinical studies1,2 patients with reduced facial skin elasticity
were treated effectively with Autologous Conditioned Serum (ACS), firmness and
hydration increased significantly through the increased cytokines and growth factor
levels (e.g. TGF-ß, IGF1) in ACS. ACS is already in use in orthopaedic indications
such as osteoarthritis and tendinopathies, anti-inflammatory effects in humans and
increased collagen type I production in animals have been described. ACS differs
from PRP especially through it’s cell-free feature and eligibility for storage.

Introduction: We present here our own experience with ACS in the regenerative anti-aging
treatment of patients in an aesthetic surgery practice in Berlin.

Materials / method: After standardised ACS processing, we treated a group of patients over 35 years via
manual microinjection technique with 4 mL ACS every two weeks (in total 4 injection
sessions). Photo documentations have been performed in addition to patient- and
physician evaluation of treated skin.

Results: ACS was effective in increasing skin firmness and hydration, patients’ and
physicians’ aesthetic satisfactions were excellent, only few injection site related
transient adverse reactions were observed.

Conclusion: Substitution of declining cytokines and growth factors in aging skin through ACS is a
new regenerative approach with patient’s own blood in a safe, easy to handle way in
daily practice.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Micrograft method improves hair growth and density were at all indicated times showing and increase total hair count and density with an increase and reduction of anagen and telogen phase, respectively.

Introduction: Androgenetic alopecia (AGA) is a hereditary androgen-dependent, progressive thinning of scalp hair affecting 60–70% of the adult population worldwide. Pharmacological treatment offers moderate results and hair transplantation represents the only permanent treatment option, even if it requires a fairly invasive surgical procedure. The Rigenera® procedure is a clinical approach to obtain autologous micrografts ready to use and able to promote derma and bone regeneration, as already reported in previous studies.

Materials / method: To make this, one hundred patients were treated with autologous micrografts and clinically evaluated after 4, 6 and 12 months from treatment. Scald dermoscopy and histological analysis were performed to assess the hair growth and histological appearance of the scalp

Results: Hair growth and density were improved at all indicated times showing an increase of total hair count and density with an increase and reduction of anagen and telogen phase, respectively. Scalp dermoscopic analysis also showed an improvement of hair density and histological analysis showed a clear amelioration of the scalp, development of new hair follicles and a beginning of cuticle formation.

Conclusion: Autologous micrografts improve the hair growth and density suggesting their use in the AGA treatment.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: The purpose of this research was the generation of data and analysis of results, which characterized the safety and effectiveness of technology of application of dermis autofibroblasts in a 2-year period after application including clinical studies and post-marketing studies. It is particularly interesting to obtain objective knowledge about duration of a synthetic activity of transplanted dermal autofibroblasts and mechanisms of qualitative and quantitative changes, occurring in human skin after their application.

Introduction: Basic molecular mechanisms are associated with the main cell population of the dermis – fibroblasts, which influence the skin aging the most. Due to aging the number of functionally active fibroblasts in the skin decreases, and their bio-synthetic activity is being reduced. The imbalance between the processes of synthesis and degradation of extracellular matrix presents, and collagen level decreases with age. There are only two commercialized technologies which are based on application of autologous dermal fibroblasts: in Russia since July 2010 (“SPRS – therapy”, № 2009/308 from July, 21th 2010, Human Stem Cells Institute) and in the US since July 2011 ( LAVIV, azficel-T, Fibrocell Science, Inc).

Materials / method: 17 patients participated in clinical studies, aged 45-65 years; post-marketing studies included 93 patients, aged 36--65 years. Skin biopsies are performed from post-auricular area in order to isolate autofibroblasts. Cells for injection are prepared in accordance with the medical technology; patients were injected twice with an interval of a 1 month with 60×10*6 (60 mln) сells by linear-retrograde method. Measurement of the results (an optical profilometry, a kutometry, a laser Doppler flowmetry, a comprehensive analysis of the clinical condition of the skin, histological examination ) was carried initially, in 1, 3, 6, 12 and 24 months after the second procedure of intradermal injection of skin's autofibroblasts.

Results: The results of the clinical study indicate that after transplantation, the autofibroblasts are entirely integrate into the derma and their biosynthetic activity persists for at least 12 months. As a result, the dermal microstructure is remodeled: the amount of collagen fibers increases, the skin thickness increases, and the blood microcirculation intensifies. The changes in dermal microstructure clinically manifest as the considerably more elastic and thick skin, while wrinkles are decreasing in number and depth. The clinical effect is developing for 6–8 months and then preserves for at least 2 years. The results of the post-marketing study confirmed the results of the clinical study.

Conclusion: The results of observation demonstrate the safety and clinical effectiveness of application of dermis autofibroblasts for correction of age-related changes of the skin. After transplantation of cultured autofibroblasts in the skin their bio-synthetic potential persists, and they produce extracellular matrix component of the dermis for at least 12 months. As a result, remodeling of the dermis microstructures is observed, which accompanied by an increase of collagen level and thickness of the dermis, and by increase of functional hemomicrocirculation, that is clinically expressed by increase of turgor and thickness of the skin, and by decrease in the number and depth of wrinkles.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Zorin V. L., Zorina A. I., Terekhov S. M., et al. Biotransplant and a way of correcting soft tissue defects. A way of obtaining biotransplant. Patent for invention RU 2281776
and status : 2006

This work was not supported by any direct or non direct funding. It is under the author's own responsability